JP2016520289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520289A5 JP2016520289A5 JP2016502049A JP2016502049A JP2016520289A5 JP 2016520289 A5 JP2016520289 A5 JP 2016520289A5 JP 2016502049 A JP2016502049 A JP 2016502049A JP 2016502049 A JP2016502049 A JP 2016502049A JP 2016520289 A5 JP2016520289 A5 JP 2016520289A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- polynucleotide
- level
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 27
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 239000000090 biomarker Substances 0.000 claims 19
- 239000000523 sample Substances 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 102000001760 Notch3 Receptor Human genes 0.000 claims 10
- 108010029756 Notch3 Receptor Proteins 0.000 claims 9
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 102000005650 Notch Receptors Human genes 0.000 claims 5
- 108010070047 Notch Receptors Proteins 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 101001005667 Homo sapiens Mastermind-like protein 2 Proteins 0.000 claims 3
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims 3
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 claims 3
- 102100025130 Mastermind-like protein 2 Human genes 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 102000046883 human NOTCH2 Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 102000045550 human NOTCH3 Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794788P | 2013-03-15 | 2013-03-15 | |
| US61/794,788 | 2013-03-15 | ||
| PCT/US2014/026094 WO2014151606A2 (en) | 2013-03-15 | 2014-03-13 | Methods of treating pancreatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520289A JP2016520289A (ja) | 2016-07-14 |
| JP2016520289A5 true JP2016520289A5 (enExample) | 2017-04-13 |
Family
ID=51581651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502049A Withdrawn JP2016520289A (ja) | 2013-03-15 | 2014-03-13 | 膵臓癌の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160030561A1 (enExample) |
| EP (1) | EP2971146A4 (enExample) |
| JP (1) | JP2016520289A (enExample) |
| KR (1) | KR20150130466A (enExample) |
| CN (1) | CN105051215A (enExample) |
| AU (1) | AU2014233736A1 (enExample) |
| CA (1) | CA2900969A1 (enExample) |
| HK (1) | HK1211322A1 (enExample) |
| IL (1) | IL240688A0 (enExample) |
| MX (1) | MX2015011386A (enExample) |
| WO (1) | WO2014151606A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| CN109690314B (zh) * | 2016-05-09 | 2022-08-02 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
| EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
| EP3610042A1 (en) * | 2017-04-14 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| WO2019203255A1 (ja) * | 2018-04-19 | 2019-10-24 | 公立大学法人横浜市立大学 | 再構成癌組織を用いた薬剤評価方法 |
| WO2023225345A1 (en) * | 2022-05-20 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Treating chemoresistant cancers with notch3 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102390A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch3 expression |
| WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| US7807630B2 (en) * | 2007-09-14 | 2010-10-05 | Vanderbilt University | Targeting of Notch3 receptor function for cancer therapy |
| CN102316897B (zh) * | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| JP2012515547A (ja) * | 2009-01-26 | 2012-07-12 | アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー | Ｎｏｔｃｈ３タンパク質発現および／またはｎｏｔｃｈ３のコード領域を調節するための手段および方法；ｃａｄａｓｉｌの処置におけるその組成物および使用 |
| PH12012500574A1 (en) * | 2009-09-30 | 2012-10-22 | Genentech Inc | Notch1-antagonist-resistant cancer(s) using notch3 antagonists |
-
2014
- 2014-03-13 HK HK15112123.8A patent/HK1211322A1/xx unknown
- 2014-03-13 CA CA2900969A patent/CA2900969A1/en not_active Abandoned
- 2014-03-13 KR KR1020157028505A patent/KR20150130466A/ko not_active Withdrawn
- 2014-03-13 AU AU2014233736A patent/AU2014233736A1/en not_active Abandoned
- 2014-03-13 JP JP2016502049A patent/JP2016520289A/ja not_active Withdrawn
- 2014-03-13 MX MX2015011386A patent/MX2015011386A/es unknown
- 2014-03-13 WO PCT/US2014/026094 patent/WO2014151606A2/en not_active Ceased
- 2014-03-13 CN CN201480016155.2A patent/CN105051215A/zh active Pending
- 2014-03-13 US US14/776,259 patent/US20160030561A1/en not_active Abandoned
- 2014-03-13 EP EP14768242.1A patent/EP2971146A4/en not_active Withdrawn
-
2015
- 2015-08-20 IL IL240688A patent/IL240688A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520289A5 (enExample) | ||
| Jain et al. | Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments | |
| JP5727484B2 (ja) | Ｉ型インターフェロン診断法 | |
| Allanore et al. | Systemic sclerosis | |
| JP2017501137A5 (enExample) | ||
| Atreya et al. | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease | |
| WO2014151606A4 (en) | Methods of treating pancreatic cancer | |
| JP2022125079A (ja) | がん転移の予後診断および処置のための方法 | |
| ES2529593T3 (es) | Marcadores de enfermedades y usos de los mismos | |
| JP6664323B2 (ja) | 神経膠芽腫を治療するための診断方法及び組成物 | |
| ES2779309T3 (es) | Método para la cuantificación de PD-L1 | |
| CA2726691C (en) | Use of oncogene nrf2 for cancer prognosis | |
| JP2016105731A5 (enExample) | ||
| JP2016516403A5 (enExample) | ||
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| JP2018078911A5 (enExample) | ||
| JP2018506045A5 (enExample) | ||
| KR20160061424A (ko) | 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 | |
| JP2019523641A5 (enExample) | ||
| JP2017511131A5 (enExample) | ||
| JP2017517507A5 (enExample) | ||
| WO2015192081A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| JP2018508532A5 (enExample) | ||
| JP2019529437A (ja) | 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法 | |
| Bhalla et al. | Discontinuing tyrosine kinase inhibitor therapy in chronic myelogenous leukemia: current understanding and future directions |